Genetic mutations in acute myeloid leukemia that influence clinical decisions

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Purpose of review A plethora of studies over the past two decades have identified many genes that are recurrently mutated in acute myeloid leukemia (AML). Although great advances have been made in understanding the role of these mutated genes in AML disease pathogenesis, to date relatively few have been demonstrated to have direct clinical relevance. Recent findings Genomic techniques have allowed for the identification of many mutated genes that appear to drive disease pathogenesis and prognosis in AML. Integrated analyses examining the co-occurrence of these genes in well annotated AML patient cohorts has helped to significantly refine prognostic models, allowing for a more nuanced selection of patients for optimal postremission therapies. Furthermore, there are emerging data that gene mutations may be useful to select patients for optimal doses and/or modalities of upfront AML therapy. Finally, mutated genes themselves hold promise as therapeutic targets, as supported by strong preclinical studies. Summary Recent advances in our knowledge of the molecular genetics of AML have significantly improved our tools for clinical decision-making and promise to identify new therapies for patients.

Original languageEnglish (US)
Pages (from-to)87-94
Number of pages8
JournalCurrent opinion in hematology
Volume21
Issue number2
DOIs
StatePublished - Mar 1 2014
Externally publishedYes

Fingerprint

Acute Myeloid Leukemia
Mutation
Genes
Therapeutics
Patient Selection
Molecular Biology

Keywords

  • Acute myeloid leukemia
  • Gene mutations
  • Molecular genetics
  • Novel therapeutics
  • Post-remission therapy

ASJC Scopus subject areas

  • Hematology

Cite this

Genetic mutations in acute myeloid leukemia that influence clinical decisions. / Chung, Stephen S.

In: Current opinion in hematology, Vol. 21, No. 2, 01.03.2014, p. 87-94.

Research output: Contribution to journalReview article

@article{6f4f582d802745cd8fdaaf86e93c3890,
title = "Genetic mutations in acute myeloid leukemia that influence clinical decisions",
abstract = "Purpose of review A plethora of studies over the past two decades have identified many genes that are recurrently mutated in acute myeloid leukemia (AML). Although great advances have been made in understanding the role of these mutated genes in AML disease pathogenesis, to date relatively few have been demonstrated to have direct clinical relevance. Recent findings Genomic techniques have allowed for the identification of many mutated genes that appear to drive disease pathogenesis and prognosis in AML. Integrated analyses examining the co-occurrence of these genes in well annotated AML patient cohorts has helped to significantly refine prognostic models, allowing for a more nuanced selection of patients for optimal postremission therapies. Furthermore, there are emerging data that gene mutations may be useful to select patients for optimal doses and/or modalities of upfront AML therapy. Finally, mutated genes themselves hold promise as therapeutic targets, as supported by strong preclinical studies. Summary Recent advances in our knowledge of the molecular genetics of AML have significantly improved our tools for clinical decision-making and promise to identify new therapies for patients.",
keywords = "Acute myeloid leukemia, Gene mutations, Molecular genetics, Novel therapeutics, Post-remission therapy",
author = "Chung, {Stephen S.}",
year = "2014",
month = "3",
day = "1",
doi = "10.1097/MOH.0000000000000024",
language = "English (US)",
volume = "21",
pages = "87--94",
journal = "Current Opinion in Hematology",
issn = "1065-6251",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Genetic mutations in acute myeloid leukemia that influence clinical decisions

AU - Chung, Stephen S.

PY - 2014/3/1

Y1 - 2014/3/1

N2 - Purpose of review A plethora of studies over the past two decades have identified many genes that are recurrently mutated in acute myeloid leukemia (AML). Although great advances have been made in understanding the role of these mutated genes in AML disease pathogenesis, to date relatively few have been demonstrated to have direct clinical relevance. Recent findings Genomic techniques have allowed for the identification of many mutated genes that appear to drive disease pathogenesis and prognosis in AML. Integrated analyses examining the co-occurrence of these genes in well annotated AML patient cohorts has helped to significantly refine prognostic models, allowing for a more nuanced selection of patients for optimal postremission therapies. Furthermore, there are emerging data that gene mutations may be useful to select patients for optimal doses and/or modalities of upfront AML therapy. Finally, mutated genes themselves hold promise as therapeutic targets, as supported by strong preclinical studies. Summary Recent advances in our knowledge of the molecular genetics of AML have significantly improved our tools for clinical decision-making and promise to identify new therapies for patients.

AB - Purpose of review A plethora of studies over the past two decades have identified many genes that are recurrently mutated in acute myeloid leukemia (AML). Although great advances have been made in understanding the role of these mutated genes in AML disease pathogenesis, to date relatively few have been demonstrated to have direct clinical relevance. Recent findings Genomic techniques have allowed for the identification of many mutated genes that appear to drive disease pathogenesis and prognosis in AML. Integrated analyses examining the co-occurrence of these genes in well annotated AML patient cohorts has helped to significantly refine prognostic models, allowing for a more nuanced selection of patients for optimal postremission therapies. Furthermore, there are emerging data that gene mutations may be useful to select patients for optimal doses and/or modalities of upfront AML therapy. Finally, mutated genes themselves hold promise as therapeutic targets, as supported by strong preclinical studies. Summary Recent advances in our knowledge of the molecular genetics of AML have significantly improved our tools for clinical decision-making and promise to identify new therapies for patients.

KW - Acute myeloid leukemia

KW - Gene mutations

KW - Molecular genetics

KW - Novel therapeutics

KW - Post-remission therapy

UR - http://www.scopus.com/inward/record.url?scp=84894029189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894029189&partnerID=8YFLogxK

U2 - 10.1097/MOH.0000000000000024

DO - 10.1097/MOH.0000000000000024

M3 - Review article

C2 - 24445361

AN - SCOPUS:84894029189

VL - 21

SP - 87

EP - 94

JO - Current Opinion in Hematology

JF - Current Opinion in Hematology

SN - 1065-6251

IS - 2

ER -